
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9098751/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate. Pharmaceutical Research, 2023, 40, 735-747.	3.5	14
2	Topical and transdermal delivery with diseased human skin: passive and iontophoretic delivery of hydrocortisone into psoriatic and eczematous skin. Drug Delivery and Translational Research, 2022, 12, 197-212.	5.8	10
3	In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. International Journal of Pharmaceutics, 2022, 616, 121540.	5.2	20
4	Transdermal Delivery of Baclofen Using Iontophoresis and Microneedles. AAPS PharmSciTech, 2022, 23, 84.	3.3	10
5	Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer. Pharmaceutics, 2022, 14, 680.	4.5	9
6	Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin. International Journal of Pharmaceutics, 2022, 618, 121693.	5.2	22
7	Characterization of microneedles and microchannels for enhanced transdermal drug delivery. Therapeutic Delivery, 2021, 12, 77-103.	2.2	10
8	A novel technique to evaluate nail softening effects of different urea formulations. Pharmaceutical Development and Technology, 2021, 26, 403-411.	2.4	0
9	Development and evaluation of a heparin gel for transdermal delivery via laser-generated micropores. Therapeutic Delivery, 2021, 12, 133-144.	2.2	9
10	Impact of Different Mixing Methods on the Performance of Suspension-Based Transdermal Delivery Systems. AAPS PharmSciTech, 2021, 22, 150.	3.3	0
11	The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. Drug Delivery and Translational Research, 2020, 10, 271-281.	5.8	3
12	Intradermal and transdermal drug delivery using microneedles – Fabrication, performance evaluation and application to lymphatic delivery. Advanced Drug Delivery Reviews, 2020, 153, 195-215.	13.7	102
13	Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression. International Journal of Pharmaceutics, 2020, 591, 120007.	5.2	14
14	Modulated delivery of donepezil using a combination of skin microporation and iontophoresis. International Journal of Pharmaceutics, 2020, 589, 119853.	5.2	21
15	In Situ Gel Formation in Microporated Skin for Enhanced Topical Delivery of Niacinamide. Pharmaceutics, 2020, 12, 472.	4.5	21
16	Topical delivery of nordihydroguaretic acid for attenuating cutaneous damage caused by arsenicals. Journal of Drug Delivery Science and Technology, 2020, 58, 101773.	3.0	0
17	Transdermal Delivery of the Free Base of 3-Fluoroamphetamine: In Vitro Skin Permeation and Irritation Potential. AAPS PharmSciTech, 2020, 21, 109.	3.3	3
18	Effect of Different Pressure-Sensitive Adhesives on Performance Parameters of Matrix-Type Transdermal Delivery Systems. Pharmaceutics, 2020, 12, 209.	4.5	22

#	Article	IF	CITATIONS
19	Evaluation of an activated carbon disposal system for safe disposal of model prescription sedative medications. Scientific Reports, 2020, 10, 2968.	3.3	7
20	Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats. International Journal of Pharmaceutics, 2020, 582, 119342.	5.2	5
21	Design and Evaluation of a Poly(Lactide-co-Glycolide)-Based In Situ Film-Forming System for Topical Delivery of Trolamine Salicylate. Pharmaceutics, 2019, 11, 409.	4.5	11
22	Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications. AAPS Journal, 2019, 21, 70.	4.4	11
23	Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV. Pharmaceutics, 2019, 11, 173.	4.5	38
24	Fabrication and characterization of hyaluronic acid microneedles to enhance delivery of magnesium ascorbyl phosphate into skin. Biomedical Microdevices, 2019, 21, 104.	2.8	23
25	In Vitro Antioxidant, Anti-Inflammatory and Skin Permeation of Myrsine africana and Its Isolated Compound Myrsinoside B. Frontiers in Pharmacology, 2019, 10, 1410.	3.5	4
26	Delivery of Methotrexate and Characterization of Skin Treated by Fabricated PLGA Microneedles and Fractional Ablative Laser. Pharmaceutical Research, 2018, 35, 68.	3.5	73
27	Qualitative and quantitative analysis of lateral diffusion of drugs in human skin. International Journal of Pharmaceutics, 2018, 544, 62-74.	5.2	16
28	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system. Journal of Pharmaceutical Analysis, 2018, 8, 349-356.	5.3	4
29	Transdermal delivery of human growth hormone via laser-generated micropores. Drug Delivery and Translational Research, 2018, 8, 450-460.	5.8	28
30	Effect of ablative laser on in vitro transungual delivery. International Journal of Pharmaceutics, 2018, 544, 402-414.	5.2	14
31	Evaluation of an activated carbon-based deactivation system for the disposal of highly abused opioid medications. Drug Development and Industrial Pharmacy, 2018, 44, 125-134.	2.0	9
32	Enhancement in the Transdermal and Localized Delivery of Honokiol Through Breast Tissue. AAPS PharmSciTech, 2018, 19, 3501-3511.	3.3	16
33	Formulation Development and Characterization of Nanoemulsion-Based Formulation for Topical Delivery of Heparinoid. Journal of Pharmaceutical Sciences, 2018, 107, 2883-2890.	3.3	23
34	Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 88-103.	4.3	141
35	Transdermal formulation of 4-benzylpiperidine for cocaine-use disorder. Journal of Drug Delivery Science and Technology, 2018, 47, 299-308.	3.0	6
36	Formulation and evaluation of 4-benzylpiperidine drug-in-adhesive matrix type transdermal patch. International Journal of Pharmaceutics, 2018, 550, 71-78.	5.2	32

#	Article	IF	CITATIONS
37	Electrically and Ultrasonically Enhanced Transdermal Delivery of Methotrexate. Pharmaceutics, 2018, 10, 117.	4.5	35
38	Transdermal Delivery of Cimetidine Across Microneedle-Treated Skin: Effect of Extent of Drug Ionization on the Permeation. Journal of Pharmaceutical Sciences, 2017, 106, 1285-1292.	3.3	9
39	Transdermal Delivery of Peptides and Proteins by Physical Methods. , 2017, , 423-437.		0
40	Effects of chemical and physical enhancement techniques on transdermal delivery of 3-fluoroamphetamine hydrochloride. International Journal of Pharmaceutics, 2017, 528, 452-462.	5.2	50
41	Fabrication, characterization and application of sugar microneedles for transdermal drug delivery. Therapeutic Delivery, 2017, 8, 249-264.	2.2	38
42	Development and evaluation of a polyvinyl alcohol based topical gel. Journal of Drug Delivery Science and Technology, 2017, 39, 210-216.	3.0	21
43	Methods to simulate rubbing of topical formulation for in vitro skin permeation studies. International Journal of Pharmaceutics, 2017, 519, 22-33.	5.2	21
44	Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. Journal of Controlled Release, 2017, 268, 159-165.	9.9	58
45	Novel in situ forming hydrogel microneedles for transdermal drug delivery. Drug Delivery and Translational Research, 2017, 7, 16-26.	5.8	49
46	Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route. Critical Reviews in Therapeutic Drug Carrier Systems, 2017, 34, 551-587.	2.2	13
47	Investigation of the Dermal Absorption and Irritation Potential of Sertaconazole Nitrate Anhydrous Gel. Pharmaceutics, 2016, 8, 21.	4.5	7
48	Transdermal Delivery of Iron Using Soluble Microneedles: Dermal Kinetics and Safety. Journal of Pharmaceutical Sciences, 2016, 105, 1196-1200.	3.3	22
49	Formulation and evaluation of sublingual delivery of piroxicam using thermosensitive polymer with an inverted Franz diffusion cell. Journal of Pharmacy and Pharmacology, 2016, 68, 26-35.	2.4	4
50	Non-Ablative Fractional Laser to Facilitate Transdermal Delivery. Journal of Pharmaceutical Sciences, 2016, 105, 3324-3332.	3.3	20
51	Role of Nanotechnology in Skin Delivery of Drugs. , 2016, , 1-13.		3
52	Intradermal and follicular delivery of adapalene liposomes. Drug Development and Industrial Pharmacy, 2016, 42, 871-879.	2.0	26
53	Development of Disposal Systems for Deactivation of Unused/Residual/Expired Medications. Pharmaceutical Research, 2016, 33, 110-124.	3.5	13
54	Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis. Journal of Drug Targeting, 2016, 24, 503-507.	4.4	9

#	Article	IF	CITATIONS
55	Formulation optimization of a drug in adhesive transdermal analgesic patch. Drug Development and Industrial Pharmacy, 2016, 42, 862-870.	2.0	12
56	Solenopsin A and analogs exhibit ceramide-like biological activity. Vascular Cell, 2015, 7, 5.	0.2	18
57	Cosmetic devices based on active transdermal technologies. Therapeutic Delivery, 2015, 6, 1089-1099.	2.2	19
58	Enhanced skin delivery of vismodegib by microneedle treatment. Drug Delivery and Translational Research, 2015, 5, 407-423.	5.8	47
59	Effect of Modulated Alternating and Direct Current Iontophoresis on Transdermal Delivery of Lidocaine Hydrochloride. BioMed Research International, 2014, 2014, 1-6.	1.9	14
60	Iontophoretic and Microneedle Mediated Transdermal Delivery of Glycopyrrolate. Pharmaceutics, 2014, 6, 663-671.	4.5	26
61	Transdermal delivery of proteins using a combination of iontophoresis and microporation. Therapeutic Delivery, 2014, 5, 525-536.	2.2	10
62	Vehicle influence on permeation through intact and compromised skin. International Journal of Pharmaceutics, 2014, 472, 362-368.	5.2	17
63	Induction and Inhibition of Crystallization in Drug-in-Adhesive-Type Transdermal Patches. Pharmaceutical Research, 2013, 30, 562-571.	3.5	23
64	Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. Journal of Drug Targeting, 2013, 21, 354-366.	4.4	41
65	Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. International Journal of Pharmaceutics, 2013, 441, 9-18.	5.2	30
66	Adapalene Microemulsion for Transfollicular Drug Delivery. Journal of Pharmaceutical Sciences, 2013, 102, 2622-2631.	3.3	54
67	Transdermal delivery of methotrexate for pediatrics using silicon microneedles. Therapeutic Delivery, 2013, 4, 543-551.	2.2	21
68	In Vivo Transdermal Delivery of Leuprolide Using Microneedles and Iontophoresis. Current Pharmaceutical Biotechnology, 2013, 14, 180-193.	1.6	0
69	In Vivo Transdermal Delivery of Leuprolide Using Microneedles and Iontophoresis. Current Pharmaceutical Biotechnology, 2013, 14, 180-193.	1.6	13
70	In vivo transdermal delivery of leuprolide using microneedles and iontophoresis. Current Pharmaceutical Biotechnology, 2013, 14, 180-93.	1.6	16
71	Evaluation of acyclovir cream and gel formulations for transdermal iontophoretic delivery. Therapeutic Delivery, 2012, 3, 327-338.	2.2	8
72	Peptide and protein transdermal drug delivery. Drug Discovery Today: Technologies, 2012, 9, e147-e154.	4.0	44

#	Article	IF	CITATIONS
73	Foreword to Transdermal Delivery Mini Focus Issue. Therapeutic Delivery, 2012, 3, 293-294.	2.2	1
74	An update on the application of physical technologies to enhance intradermal and transdermal drug delivery. Therapeutic Delivery, 2012, 3, 339-355.	2.2	15
75	Transcending the Skin Barrier to Deliver Peptides and Proteins Using Active Technologies. Critical Reviews in Therapeutic Drug Carrier Systems, 2012, 29, 265-298.	2.2	25
76	In Vivo Iontophoretic Delivery of Salmon Calcitonin Across Microporated Skin. Journal of Pharmaceutical Sciences, 2012, 101, 2861-2869.	3.3	20
77	Low frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. International Journal of Pharmaceutics, 2012, 423, 289-296.	5.2	77
78	Delivery of salmon calcitonin using a microneedle patch. International Journal of Pharmaceutics, 2012, 423, 257-263.	5.2	58
79	Modulated iontophoretic delivery of small and large molecules through microchannels. International Journal of Pharmaceutics, 2012, 434, 106-114.	5.2	43
80	Transdermal Delivery of Peptides and Proteins. , 2011, , 69-86.		6
81	Transdermal Iontophoretic Delivery of Hydrocortisone from Cyclodextrin Solutions. Journal of Pharmacy and Pharmacology, 2011, 50, 635-640.	2.4	30
82	Aggregation of Proteins and its Prevention by Carbohydrate Excipients: Albumins and γ-Globulin. Journal of Pharmacy and Pharmacology, 2011, 47, 103-107.	2.4	35
83	Microneedles and their Applications. Recent Patents on Drug Delivery and Formulation, 2011, 5, 95-132.	2.1	51
84	Effects of Chemical and Physical Enhancement Techniques on Transdermal Delivery of Cyanocobalamin (Vitamin B12) In Vitro. Pharmaceutics, 2011, 3, 474-484.	4.5	30
85	Acyclovir skin depot characterization following <i>in vivo</i> iontophoretic delivery. Skin Research and Technology, 2011, 17, 234-244.	1.6	16
86	Characterization of Microchannels Created by Metal Microneedles: Formation and Closure. AAPS Journal, 2011, 13, 473-481.	4.4	106
87	Transdermal Delivery of Proteins. AAPS PharmSciTech, 2011, 12, 431-441.	3.3	130
88	Formation and Closure of Microchannels in Skin Following Microporation. Pharmaceutical Research, 2011, 28, 82-94.	3.5	110
89	Iontophoretic Delivery of Acyclovir: Intradermal Drug Monitoring Using Microdialysis and Quantification by Skin Extraction. PDA Journal of Pharmaceutical Science and Technology, 2011, 65, 432-444.	0.5	7
90	lontophoresis of a 13 kDa protein monitored by subcutaneous microdialysisin vivo. Bioanalysis, 2011, 3, 2419-2426.	1.5	7

#	Article	IF	CITATIONS
91	Response Surface Methodology to Optimize Novel Fast Disintegrating Tablets Using β Cyclodextrin as Diluent. AAPS PharmSciTech, 2010, 11, 1627-1635.	3.3	19
92	Electrically enhanced transdermal delivery of a macromolecule. Journal of Pharmacy and Pharmacology, 2010, 54, 907-912.	2.4	28
93	Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. Journal of Pharmacy and Pharmacology, 2010, 60, 27-33.	2.4	84
94	Microchannels created by sugar and metal microneedles: Characterization by microscopy, macromolecular flux and other techniques. Journal of Pharmaceutical Sciences, 2010, 99, 1931-1941.	3.3	52
95	Transdermal iontophoretic delivery of terbinafine hydrochloride: Quantitation of drug levels in stratum corneum and underlying skin. International Journal of Pharmaceutics, 2010, 388, 24-31.	5.2	30
96	Iontophoresis mediated in vivo intradermal delivery of terbinafine hydrochloride. International Journal of Pharmaceutics, 2010, 393, 113-119.	5.2	19
97	Inhibition of crystallization in drug-in-adhesive-type transdermal patches. International Journal of Pharmaceutics, 2010, 394, 68-74.	5.2	59
98	Transdermal delivery of a ~13 kDa protein—anin vivocomparison of physical enhancement methods. Journal of Drug Targeting, 2010, 18, 141-147.	4.4	25
99	Transdermal and intradermal iontophoretic delivery of dexamethasone sodium phosphate: quantification of the drug localized in skin. Journal of Drug Targeting, 2010, 18, 134-140.	4.4	17
100	Enhancement of Transdermal Delivery of Heparin by Various Physical and Chemical Enhancement Techniques. Critical Reviews in Therapeutic Drug Carrier Systems, 2009, 26, 581-606.	2.2	10
101	Molecular charge mediated transport of a 13kD protein across microporated skin. International Journal of Pharmaceutics, 2009, 378, 93-100.	5.2	46
102	In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. International Journal of Pharmaceutics, 2009, 368, 109-115.	5.2	171
103	Microporation applications for enhancing drug delivery. Expert Opinion on Drug Delivery, 2009, 6, 343-354.	5.0	123
104	Transdermal and intradermal iontophoretic delivery of dexamethasone sodium phosphate: quantification of the drug localized in skin. Journal of Drug Targeting, 2009, 00, 090922082920054-7.	4.4	1
105	Characterization of Solid Maltose Microneedles and their Use for Transdermal Delivery. Pharmaceutical Research, 2008, 25, 104-113.	3.5	180
106	Optimization of lontophoretic Parameters for the Transdermal Delivery of Methotrexate. Drug Delivery, 2008, 15, 437-442.	5.7	20
107	Transdermal Delivery of Interferon Alpha-2B using Microporation and Iontophoresis in Hairless Rats. Pharmaceutical Research, 2007, 24, 1389-1395.	3.5	83
108	Theme Section: Transdermal Delivery of Proteins. Pharmaceutical Research, 2007, 24, 1357-1359.	3.5	13

#	Article	IF	CITATIONS
109	New Technologies to Allow Transdermal Delivery of Therapeutic Proteins and Small Water-Soluble Drugs. American Journal of Drug Delivery, 2006, 4, 221-230.	0.6	19
110	Application of TZERO calibrated modulated temperature differential scanning calorimetry to characterize model protein formulations. International Journal of Pharmaceutics, 2006, 309, 146-156.	5.2	11
111	In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. International Journal of Pharmaceutics, 2005, 297, 190-6.	5.2	30
112	Factorial design approach to evaluate interactions between electrically assisted enhancement and skin stripping for delivery of tacrine. Journal of Controlled Release, 2005, 103, 113-121.	9.9	24
113	Dermal, Subdermal, and Systemic Concentrations of Granisetron by Iontophoretic Delivery. Pharmaceutical Research, 2005, 22, 1313-1319.	3.5	42
114	Response Surface Methodology to Investigate the Iontophoretic Delivery of Tacrine Hydrochloride. Pharmaceutical Research, 2004, 21, 2293-2299.	3.5	36
115	Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. Pharmaceutical Research, 2003, 20, 1496-1501.	3.5	17
116	Stability of a Transdermal Salmon Calcitonin Formulation. Drug Delivery, 2003, 10, 41-45.	5.7	8
117	Electrically modulated transdermal delivery of fentanyl. Pharmaceutical Research, 2002, 19, 440-444.	3.5	20
118	Transdermal iontophoretic delivery of salmon calcitonin. International Journal of Pharmaceutics, 2000, 200, 107-113.	5.2	53
119	The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. Journal of Controlled Release, 2000, 66, 127-133.	9.9	97
120	Iontophoresis and electroporation: comparisons and contrasts. International Journal of Pharmaceutics, 1999, 179, 1-19.	5.2	182
121	Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends in Biotechnology, 1998, 16, 408-412.	9.3	83
122	Clinical Applications of lontophoretic Devices in Rehabilitation Medicine. Critical Reviews in Physical and Rehabilitation Medicine, 1998, 10, 147-179.	0.1	18
123	Use of Poloxamer Polymers to Stabilize Recombinant Human Growth Hormone Against Various Processing Stresses. Pharmaceutical Development and Technology, 1997, 2, 143-149.	2.4	68
124	Transdermal iontophoretic delivery of ketoprofen through human cadaver skin and in humans. Journal of Controlled Release, 1997, 44, 113-121.	9.9	38
125	Transdermal lontophoretic delivery of colchicine encapsulated in liposomes. Drug Delivery, 1996, 3, 245-250.	5.7	10
126	Transdermal iontophoretic delivery and degradation of vasopressin across human cadaver skin. International Journal of Pharmaceutics, 1995, 116, 211-216.	5.2	29

#	Article	IF	CITATIONS
127	Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharmaceutical Research, 1993, 10, 697-702.	3.5	77
128	Characterization of in Vitro Transdermal Iontophoretic Delivery of Insulin. Drug Development and Industrial Pharmacy, 1993, 19, 2069-2087.	2.0	25
129	Iontophoretic delivery of drugs: Fundamentals, developments and biomedical applications. Journal of Controlled Release, 1988, 7, 1-24.	9.9	208